查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1844188

人類免疫力缺乏病毒治療藥物市場（依藥物類別、治療方案類型、治療線、劑型、患者類型和分銷管道分類）－2025-2032年全球預測

Human Immunodeficiency Virus Therapeutics Market by Drug Class, Regimen Type, Therapy Line, Mode Of Administration, Patient Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，人類免疫力缺乏病毒 (HIV) 治療市場將成長至 293.2 億美元，複合年成長率為 4.71%。

主要市場統計數據
基準年 2024 202.8億美元
預計年份：2025年 212.3億美元
預測年份：2032年 293.2億美元
複合年成長率 (%) 4.71%

本文首先概述了影響當代愛滋病治療策略的臨床進展、政策發展和相關人員需求，並以此為背景展開論述。

人類免疫力缺乏病毒治療領域格局的不斷演變，需要一個介紹性的框架，將近期臨床進展、監管環境和商業性動態納入一個連貫的策略敘事之中。該框架綜合了從抗逆轉錄病毒聯合治療到當前重點領域（例如長效製劑、簡化方案和差異化治療路徑）的科學發展軌跡，同時也承認擴大公平獲取途徑和降低發病率這一持續存在的公共衛生迫切需求。

此外，引言部分重點闡述了相關人員——臨床醫生、支付方、生產者和患者權益倡導者——的觀點，並著重強調了臨床療效、耐受性和依從性如何影響治療方法的選擇和商業化。引言也強調了治療方法創新與醫療系統動態之間的相互關係，指出劑型變化和治療方案複雜性如何直接影響供應鏈和分銷策略。因此，該框架為後續章節深入分析監管趨勢、競爭動態和市場細分奠定了基礎，從而為決策者提供了所需的背景資訊，以便他們優先考慮投資、政策參與和戰略夥伴關係。

檢驗了科學創新、監管變革以及患者和支付方期望的轉變為愛滋病治療帶來的變革性變化。

愛滋病治療領域正經歷變革性的轉變，這主要得益於科學突破、監管環境的變化以及患者期望的不斷提高，這些因素正在重新定義治療標準和商業性機會。整合酵素抑制劑和長效注射等創新療法透過提高療效、耐受性和依從性，正在改變治療模式，促使製劑研發者和患者優先選擇能夠減少服藥負擔並支持持久病毒抑制的治療方案。

同時，監管核准管道正在調整，以加快核准那些能夠顯著改善患者依從性和生活品質的產品；而支付方和採購機構則日益重視醫療總成本和基本契約。此外，隨著社區主導計畫和線上藥局的覆蓋範圍不斷擴大，差異化醫療模式和分散式服務模式的日益普及正在重塑分銷管道。因此，製藥公司必須在創新、可負擔性和供應可靠性之間取得平衡，將以患者為中心的臨床開發與務實的商業化策略相結合，從而在實現公共衛生目標的同時創造價值。

分析2025年美國關稅政策如何改變愛滋病治療生態系統的供應鏈、籌資策略和生產決策。

美國2025年實施的關稅和貿易措施對愛滋病治療價值鏈產生了複雜的影響，波及籌資策略、製造地選擇和跨境供應可靠性。製造商和經銷商面臨利潤率和物流成本結構的更大壓力，促使許多企業重新評估籌資策略，並探索近岸外包和雙重採購模式，以降低關稅波動帶來的風險。因此，採購負責人和醫療系統面臨複雜的合約談判，需要考慮與關稅相關的附加稅和更長的交貨前置作業時間。

此外，關稅政策改變了對國內生產能力和戰略儲備投資的考量，並加速了關鍵抗逆轉錄病毒和重要原料藥的韌性和自給自足能力的討論。為此，一些相關人員加強了與免稅國家和地區的契約製造和出口商的合作，而另一些利益相關者則加快了監管協調方面的投資，以簡化跨境分銷。總而言之，這些相關人員凸顯了在貿易中斷的情況下，供應鏈彈性和積極參與知情措施對於維持病患用藥和專案連續性的策略必要性。

透過整合藥物類別、治療方案類型、治療線、劑型、患者類型和分銷管道等關鍵細分洞察，明確您的策略。

精細的細分視角清晰地展現了臨床、商業和營運重點的交匯點，為跨產品系列和通路策略的策略決策提供了結構性基礎。按藥物類別分類，涵蓋了入口點抑制劑、整合酶鏈轉移抑制劑、非核苷類逆轉錄酶抑制劑、核苷類逆轉錄酶抑制劑和蛋白酶抑制劑。入口點抑制劑包括恩夫韋地和馬拉維羅克；整合酶抑制劑包括比克替拉韋、多替拉韋、埃爾維特格拉韋和拉替拉韋；非核苷類逆轉錄酶抑制劑包括依非韋倫、依曲韋林、奈韋拉平和利匹韋林；核苷類逆轉錄酶抑制劑包括阿巴卡韋、恩曲他濱、拉米夫定、替諾福韋和齊多夫定；蛋白酶抑制劑包括阿扎那韋、達蘆那韋、福沙那韋和洛匹那韋。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 長效注射抗逆轉錄病毒療法在愛滋病治療的研發和臨床試驗結果
  • 擴大通用學名藥諾福韋艾拉酚胺的取得途徑及其對低收入社區可負擔性的影響
  • 廣譜中和抗體作為被動免疫療法在愛滋病毒預防和治療的應用進展
  • 將數位化依從性工具與行動醫療平台整合，以提高高風險族群的抗愛滋病毒療法依從性
  • 利用潛伏期逆轉藥物和免疫調節劑靶向HIV病毒庫的聯合治療策略研發取得進展
  • First-in-Class衣殼抑制劑在初治患者和經治患者中的監管核准和市場接受度
  • 雙藥聯合治療策略的出現及其對簡化長期愛滋病治療通訊協定的影響
  • 暴露前預防創新技術（包括長效植入和多用途預防技術）的作用
  • 健康政策轉變與全球資金趨勢對撒哈拉以南非洲兒童愛滋病藥物可近性的影響
  • 利用真實世界證據和患者報告結果評估新型 HIV 療法的療效和安全性

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

8. 按藥物類別分類的人類免疫力缺乏病毒治療市場

  • 進入抑制劑
    • 恩夫韋地
    • 馬拉威羅克
  • 整合酶鏈轉移抑制劑
    • 比克替拉韋
    • 多替拉韋
    • 埃爾維特格拉維爾
    • 拉特格拉維爾
  • 非核苷類逆轉錄酶抑制劑
    • 依非韋倫
    • 依曲韋林
    • 奈韋拉平
    • 利匹韋林
  • 核苷類逆轉錄酶抑制劑
    • 阿巴卡韋
    • 恩曲他濱
    • 拉米夫定
    • 替諾福韋
    • 齊多夫定
  • 蛋白酶抑制劑
    • 阿扎那韋
    • 達蘆那韋
    • 福沙那韋
    • 洛匹那韋

9. 依治療方案類型分類的人類免疫力缺乏病毒治療市場

  • 多藥丸療法
  • 單片服用方案

10. 按治療線分類的人類免疫力缺乏病毒治療市場

  • 主要治療
  • 挽救性治療
  • 二級治療

11. 人類免疫力缺乏病毒治療藥物市場（依劑型分類）

  • 注射
  • 口服

12. 依患者類型分類的人類免疫力缺乏病毒治療市場

  • 成人
  • 孩子們

13. 人類免疫力缺乏病毒治療藥物市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

14. 各地區人類免疫力缺乏病毒治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

15. 按組別分類的人類免疫力缺乏病毒治療市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各國人類免疫力缺乏病毒治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Gilead Sciences, Inc.
    • ViiV Healthcare Limited
    • Merck & Co., Inc.
    • Janssen Pharmaceutica NV
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
    • Shionogi & Co., Ltd.
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Cipla Limited
Product Code: MRR-ED54C46E8CF6

The Human Immunodeficiency Virus Therapeutics Market is projected to grow by USD 29.32 billion at a CAGR of 4.71% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 20.28 billion
Estimated Year [2025] USD 21.23 billion
Forecast Year [2032] USD 29.32 billion
CAGR (%) 4.71%

Introductory framing that contextualizes clinical advances, policy developments, and stakeholder imperatives shaping contemporary HIV therapeutic strategies

The evolving landscape of human immunodeficiency virus therapeutics demands an introductory framework that situates recent clinical advances, regulatory milestones, and commercial dynamics within a coherent strategic narrative. This introduction synthesizes the scientific trajectory from combination antiretroviral therapy to contemporary priorities such as long-acting formulations, simplified regimens, and differentiated care pathways, while also acknowledging the persistent public health imperative to expand equitable access and reduce morbidity.

Moreover, the introduction clarifies stakeholder perspectives across clinicians, payers, manufacturers, and patient advocates, highlighting how clinical efficacy, tolerability, and real-world adherence shape treatment selection and commercialization. It delineates the interplay between therapeutic innovation and health system capacity, emphasizing how shifts in administration modality and regimen complexity have direct implications for supply chains and distribution strategies. Consequently, this framing sets expectations for deeper sections that analyze regulatory trends, competitive dynamics, and market segmentation, thereby equipping decision-makers with the context needed to prioritize investment, policy engagement, and strategic partnerships.

Examining the major transformative shifts in HIV therapeutics driven by scientific innovation, regulatory change, and evolving patient and payer expectations

The therapeutic landscape for HIV has undergone transformative shifts driven by scientific breakthroughs, regulatory evolution, and changing patient expectations, which together are redefining standard-of-care and commercial opportunity. Innovations such as integrase inhibitors and long-acting injectable formulations have altered treatment paradigms by improving potency, tolerability, and adherence profiles, thereby encouraging prescribers and patients to prioritize regimens that reduce pill burden and support sustained viral suppression.

Concurrently, regulatory pathways have adapted to accommodate faster approvals for formulations that demonstrate meaningful improvements in adherence and quality of life, while payers and procurement agencies are increasingly emphasizing total cost of care and outcomes-based contracting. Moreover, the expanded focus on differentiated care models and decentralized delivery is reshaping distribution channels, as community-led programs and online pharmacies amplify reach. As a result, pharmaceutical companies must balance innovation with affordability and supply reliability, integrating patient-centered clinical development with pragmatic commercialization strategies to capture value while advancing public health goals.

Analyzing how the 2025 United States tariff measures reshaped supply chains, procurement strategies, and manufacturing decisions across the HIV therapeutics ecosystem

The imposition of tariffs and trade measures by the United States in 2025 introduced a complex set of effects across the HIV therapeutic value chain, influencing procurement strategies, manufacturing location decisions, and cross-border supply reliability. Manufacturers and distributors experienced increased pressure on margins and logistical cost structures, prompting many to reassess sourcing strategies and to explore nearshoring or dual-sourcing arrangements to mitigate exposure to tariff volatility. Consequently, procurement officers and health systems faced heightened complexity when negotiating contracts that now needed to account for contingent tariff-related surcharges and longer lead times.

Moreover, tariffs altered the calculus for investment in domestic production capacity and strategic stockpiling, accelerating conversations around resilience and self-sufficiency for critical antiretrovirals and key active pharmaceutical ingredients. In response, several stakeholders intensified collaboration with contract manufacturers and exporters in tariff-exempt jurisdictions, while others accelerated investments in regulatory harmonization to streamline cross-border distribution. These adaptive measures, taken together, underscore the strategic necessity of supply chain agility and informed policy engagement to preserve patient access and maintain program continuity amid trade-induced disruption.

Critical segmentation insights that integrate drug class, regimen type, therapy line, administration mode, patient type, and distribution channel for strategic clarity

A granular segmentation lens clarifies where clinical, commercial, and operational priorities converge, providing a structured basis for strategic decision-making across product portfolios and channel strategies. Based on drug class, analysis spans Entry Inhibitors, Integrase Strand Transfer Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Nucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors, with Entry Inhibitors examined through Enfuvirtide and Maraviroc; Integrase inhibitors covered via Bictegravir, Dolutegravir, Elvitegravir, and Raltegravir; Non-Nucleoside reverse transcriptase inhibitors considered through Efavirenz, Etravirine, Nevirapine, and Rilpivirine; Nucleoside reverse transcriptase inhibitors analyzed including Abacavir, Emtricitabine, Lamivudine, Tenofovir, and Zidovudine; and Protease Inhibitors evaluated through Atazanavir, Darunavir, Fosamprenavir, and Lopinavir.

Based on regimen type, the landscape distinguishes between Multi Tablet Regimen and Single Tablet Regimen, recognizing that simplification of dosing remains a central driver of adherence and therapeutic persistence. Based on therapy line, segmentation includes First Line, Salvage Therapy, and Second Line, which informs development priorities for agents intended for treatment-experienced populations or for use where resistance patterns constrain options. Based on mode of administration, the analysis contrasts Injectable and Oral modalities, reflecting the commercial and operational ramifications of long-acting injectables versus daily oral therapies. Based on patient type, differentiation between Adult and Pediatric populations highlights formulation needs, palatability, and dosing considerations that influence pediatric program design. Finally, based on distribution channel, the framework examines Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy dynamics, recognizing that channel-specific procurement, reimbursement, and adherence support models materially affect uptake and access.

Key regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access pathways, regulation, and commercialization strategies

Regional dynamics materially influence clinical adoption, access pathways, and commercial strategies for HIV therapeutics, with each geography presenting distinct regulatory, payer, and delivery considerations. In the Americas, mature regulatory frameworks, established treatment guidelines, and concentrated payer negotiation leverage drive demand for differentiated regimens and outcomes-based contracting, while supply chain complexity necessitates robust distribution partnerships and patient support programs.

Across Europe, Middle East & Africa, heterogeneity in regulatory capacity, procurement models, and health system financing shapes varied adoption patterns; high-income markets prioritize innovation and formulary placement, whereas middle- and low-income settings emphasize affordability, generic competition, and procurement through pooled purchasing mechanisms. In Asia-Pacific, a mix of large domestic manufacturers, progressive regulatory reform in certain jurisdictions, and rapidly evolving private and public payer arrangements create opportunities for localized manufacturing, tiered pricing strategies, and digital health-enabled adherence interventions. Taken together, these regional distinctions underscore the need for tailored commercialization and access strategies that reflect regulatory timelines, procurement structures, and patient population characteristics.

Strategic company-level insights detailing how originators, biotech innovators, generics, and manufacturing partners shape competition and access in HIV therapeutics

Leading companies and strategic entrants each play distinct roles in shaping the HIV therapeutics ecosystem through pipeline investment, partnership models, and manufacturing scale. Originator pharmaceutical firms continue to invest in next-generation molecules, long-acting platforms, and novel delivery systems, leveraging clinical differentiation to pursue premium placements while managing lifecycle strategies against generic erosion. At the same time, biotechnology firms drive innovation with nimble development of first-in-class mechanisms and biologic approaches, frequently collaborating with larger partners to access development expertise and commercial reach.

Generic manufacturers and contract development and manufacturing organizations serve as critical pillars for affordability and supply resilience, particularly in regions where price sensitivity and centralized procurement dominate. Strategic partnerships, licensing agreements, and targeted acquisitions have become common tactics for companies seeking to quickly expand therapeutic breadth or to secure manufacturing capacity. In parallel, technology and digital health companies are increasingly adjacent players, offering adherence support, remote monitoring, and patient engagement solutions that enhance the real-world effectiveness of therapeutics. Together, these actors create an ecosystem where commercial success depends on scientific differentiation, strategic alliances, and the ability to operationalize distribution and patient support at scale.

Practical and actionable recommendations for industry leaders to align therapeutic innovation with resilient supply chains, payer engagement, and patient-centered delivery

Industry leaders should prioritize a suite of actionable strategies that align scientific innovation with supply resilience, payer engagement, and patient-centered delivery models to capture value while improving public health outcomes. First, firms ought to strengthen supply chain diversification by establishing multiple sourcing lanes, qualifying alternative manufacturers, and incorporating contingency inventory practices to guard against trade and logistics disruptions. Second, investment in long-acting formulations and simplified regimens should be paired with targeted evidence generation that demonstrates adherence benefits and health system efficiencies, thereby easing payer acceptance and formulary uptake.

Furthermore, organizations need to actively engage payers and procurement bodies early in development to design value propositions that speak to total cost of care, adherence outcomes, and real-world effectiveness. Concurrently, advancing pediatric-friendly formulations and pragmatic administration models will address persistent access gaps. Companies should also leverage partnerships for local manufacturing or technology transfer where appropriate, enabling tiered pricing and faster market entry. Finally, integrating digital adherence tools and patient support programs into commercialization plans will strengthen therapy persistence and outcomes. These recommendations collectively offer a roadmap for aligning innovation with pragmatic execution across clinical, regulatory, and commercial domains.

Comprehensive research methodology that integrates primary interviews, secondary literature review, and triangulation to validate insights and strategic implications

The research methodology underpinning this analysis combines rigorous primary and secondary approaches to ensure reliability, relevance, and reproducibility of insights. Primary research involved structured interviews and qualitative discussions with a cross-section of clinicians, procurement specialists, payers, key opinion leaders, and industry executives, enabling the capture of real-world perspectives on clinical practice, reimbursement dynamics, and operational constraints. These conversations were designed to surface drivers of treatment choice, barriers to access, and strategic priorities across stakeholder groups.

Secondary research complemented primary inputs through systematic review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available company disclosures to validate clinical and regulatory trends. Data triangulation techniques were applied to reconcile divergent sources and to strengthen confidence in thematic conclusions. Analytical rigor was further enhanced via scenario analysis and sensitivity checks to assess the robustness of strategic implications under varying assumptions. Ethical considerations, including the protection of participant confidentiality and avoidance of commercial bias, were integral to the research process, and limitations related to regional data granularity and rapidly evolving clinical evidence were transparently acknowledged.

Conclusive synthesis emphasizing strategic alignment of clinical innovation, payer engagement, and resilient operations to advance HIV therapeutic access and outcomes

In conclusion, the contemporary HIV therapeutics environment is characterized by meaningful clinical innovation, shifting regulatory and payer expectations, and a heightened focus on supply chain resilience and equitable access. Integrase inhibitors and long-acting modalities exemplify how therapeutic advances can translate into improved adherence and patient experience, while the commercial reality underscores the need for holistic strategies that reconcile innovation with affordability and distribution reliability. Consequently, stakeholders must adopt integrated approaches that bridge clinical differentiation with pragmatic operational execution.

Looking ahead, organizations that successfully align robust evidence generation, proactive payer engagement, and diversified manufacturing and distribution capabilities will be best positioned to deliver both commercial value and public health impact. Continued collaboration across industry, payers, providers, and community organizations will remain essential to translate therapeutic advances into durable improvements in treatment outcomes and access. Ultimately, strategic agility, evidence-based value propositions, and patient-centered delivery models will determine which programs attain sustainable success in this dynamic therapeutic arena.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Development and clinical trial results of long-acting injectable antiretroviral therapies for HIV management
  • 5.2. Expansion of generic tenofovir alafenamide access and impact on treatment affordability in low-income regions
  • 5.3. Advancement of broadly neutralizing antibodies as passive immunotherapy options for HIV prevention and treatment
  • 5.4. Integration of digital adherence tools and mobile health platforms to enhance ART compliance among high-risk populations
  • 5.5. Pipeline progress of combination cure strategies targeting HIV reservoirs with latency-reversing agents and immune modulators
  • 5.6. Regulatory approval and market uptake of first-in-class capsid inhibitors in treatment-naive and treatment-experienced patients
  • 5.7. Emergence of two-drug regimen strategies and their impact on simplifying long-term HIV therapy protocols
  • 5.8. Role of preexposure prophylaxis innovation including long-acting implants and multipurpose prevention technologies
  • 5.9. Impact of health policy shifts and global funding dynamics on access to pediatric HIV formulations in sub-Saharan Africa
  • 5.10. Adoption of real-world evidence and patient-reported outcomes in evaluating novel HIV therapeutic effectiveness and safety

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Immunodeficiency Virus Therapeutics Market, by Drug Class

  • 8.1. Entry Inhibitors
    • 8.1.1. Enfuvirtide
    • 8.1.2. Maraviroc
  • 8.2. Integrase Strand Transfer Inhibitors
    • 8.2.1. Bictegravir
    • 8.2.2. Dolutegravir
    • 8.2.3. Elvitegravir
    • 8.2.4. Raltegravir
  • 8.3. Non-Nucleoside Reverse Transcriptase Inhibitors
    • 8.3.1. Efavirenz
    • 8.3.2. Etravirine
    • 8.3.3. Nevirapine
    • 8.3.4. Rilpivirine
  • 8.4. Nucleoside Reverse Transcriptase Inhibitors
    • 8.4.1. Abacavir
    • 8.4.2. Emtricitabine
    • 8.4.3. Lamivudine
    • 8.4.4. Tenofovir
    • 8.4.5. Zidovudine
  • 8.5. Protease Inhibitors
    • 8.5.1. Atazanavir
    • 8.5.2. Darunavir
    • 8.5.3. Fosamprenavir
    • 8.5.4. Lopinavir

9. Human Immunodeficiency Virus Therapeutics Market, by Regimen Type

  • 9.1. Multi Tablet Regimen
  • 9.2. Single Tablet Regimen

10. Human Immunodeficiency Virus Therapeutics Market, by Therapy Line

  • 10.1. First Line
  • 10.2. Salvage Therapy
  • 10.3. Second Line

11. Human Immunodeficiency Virus Therapeutics Market, by Mode Of Administration

  • 11.1. Injectable
  • 11.2. Oral

12. Human Immunodeficiency Virus Therapeutics Market, by Patient Type

  • 12.1. Adult
  • 12.2. Pediatric

13. Human Immunodeficiency Virus Therapeutics Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Human Immunodeficiency Virus Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Human Immunodeficiency Virus Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Human Immunodeficiency Virus Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Gilead Sciences, Inc.
    • 17.3.2. ViiV Healthcare Limited
    • 17.3.3. Merck & Co., Inc.
    • 17.3.4. Janssen Pharmaceutica NV
    • 17.3.5. Bristol-Myers Squibb Company
    • 17.3.6. Pfizer Inc.
    • 17.3.7. Shionogi & Co., Ltd.
    • 17.3.8. Viatris Inc.
    • 17.3.9. Teva Pharmaceutical Industries Ltd.
    • 17.3.10. Cipla Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENFUVIRTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENFUVIRTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENFUVIRTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENFUVIRTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENFUVIRTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENFUVIRTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MARAVIROC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MARAVIROC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MARAVIROC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MARAVIROC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MARAVIROC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MARAVIROC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY BICTEGRAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY BICTEGRAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY BICTEGRAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY BICTEGRAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY BICTEGRAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY BICTEGRAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DOLUTEGRAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DOLUTEGRAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DOLUTEGRAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DOLUTEGRAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DOLUTEGRAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DOLUTEGRAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ELVITEGRAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ELVITEGRAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ELVITEGRAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ELVITEGRAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ELVITEGRAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ELVITEGRAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RALTEGRAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RALTEGRAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RALTEGRAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RALTEGRAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RALTEGRAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RALTEGRAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EFAVIRENZ, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EFAVIRENZ, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EFAVIRENZ, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EFAVIRENZ, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EFAVIRENZ, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EFAVIRENZ, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ETRAVIRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ETRAVIRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ETRAVIRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ETRAVIRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ETRAVIRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ETRAVIRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NEVIRAPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NEVIRAPINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NEVIRAPINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NEVIRAPINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NEVIRAPINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NEVIRAPINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RILPIVIRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RILPIVIRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RILPIVIRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RILPIVIRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RILPIVIRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RILPIVIRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ABACAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ABACAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ABACAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ABACAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ABACAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ABACAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EMTRICITABINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EMTRICITABINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EMTRICITABINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EMTRICITABINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LAMIVUDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LAMIVUDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LAMIVUDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LAMIVUDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LAMIVUDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LAMIVUDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY TENOFOVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY TENOFOVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY TENOFOVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY TENOFOVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY TENOFOVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY TENOFOVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ZIDOVUDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ZIDOVUDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ZIDOVUDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ZIDOVUDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ZIDOVUDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ZIDOVUDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ATAZANAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ATAZANAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ATAZANAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ATAZANAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ATAZANAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ATAZANAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DARUNAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DARUNAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DARUNAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DARUNAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DARUNAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DARUNAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FOSAMPRENAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FOSAMPRENAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FOSAMPRENAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FOSAMPRENAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FOSAMPRENAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FOSAMPRENAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LOPINAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LOPINAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LOPINAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LOPINAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LOPINAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LOPINAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MULTI TABLET REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MULTI TABLET REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MULTI TABLET REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MULTI TABLET REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MULTI TABLET REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MULTI TABLET REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SINGLE TABLET REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SINGLE TABLET REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SINGLE TABLET REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SINGLE TABLET REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SINGLE TABLET REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SINGLE TABLET REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SALVAGE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SALVAGE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SALVAGE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SALVAGE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SALVAGE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SALVAGE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MA